Literature DB >> 19132351

The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure.

Allison M Mott1, Eric J Nunes, Lyndsey E Collins, Russell G Port, Kelly S Sink, Jörg Hockemeyer, Christa E Müller, John D Salamone.   

Abstract

RATIONALE: Mesolimbic dopamine (DA) is a critical component of the brain circuitry regulating behavioral activation and effort-related processes. Research involving choice tasks has shown that rats with impaired DA transmission reallocate their instrumental behavior away from food-reinforced tasks with high response requirements and instead select less effortful food-seeking behaviors.
OBJECTIVE: Previous work showed that adenosine A(2A) antagonism can reverse the effects of the DA antagonist haloperidol in an operant task that assesses effort-related choice. The present work used a T-maze choice procedure to assess the effects of adenosine A(2A) and A(1) antagonism.
MATERIALS AND METHODS: With this task, the two arms of the maze have different reinforcement densities (four vs. two food pellets), and a vertical 44 cm barrier is positioned in the arm with the higher density, presenting the animal with an effort-related challenge. Untreated rats strongly prefer the arm with the high density of food reward and climb the barrier in order to obtain the food.
RESULTS: Haloperidol produced a dose-related (0.05-0.15 mg/kg i.p.) reduction in the number of trials in which the rats chose the high-barrier arm. Co-administration of the adenosine A(2A) receptor antagonist MSX-3 (0.75, 1.5, and 3.0 mg/kg i.p.), but not the A(1) antagonist 8-cyclopentyl-1,3-dipropylxanthine (0.75, 1.5, and 3.0 mg/kg i.p.), reversed the effects of haloperidol on effort-related choice and latency.
CONCLUSIONS: Adenosine A(2A) and D2 receptors interact to regulate effort-related decision making, which may have implications for the treatment of psychiatric symptoms such as psychomotor slowing or anergia that can be observed in depression, parkinsonism, and other disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19132351      PMCID: PMC2875244          DOI: 10.1007/s00213-008-1441-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  70 in total

Review 1.  Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.

Authors:  K Fuxe; L F Agnati; K Jacobsen; J Hillion; M Canals; M Torvinen; B Tinner-Staines; W Staines; D Rosin; A Terasmaa; P Popoli; G Leo; V Vergoni; C Lluis; F Ciruela; R Franco; S Ferré
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

2.  Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats.

Authors:  Keita Ishiwari; Lisa J Madson; Andrew M Farrar; Susana M Mingote; John P Valenta; Michael D DiGianvittorio; Lauren E Frank; Merce Correa; Jörg Hockemeyer; Christa Müller; John D Salamone
Journal:  Behav Brain Res       Date:  2006-12-21       Impact factor: 3.332

Review 3.  Discrete neurochemical coding of distinguishable motivational processes: insights from nucleus accumbens control of feeding.

Authors:  Brian A Baldo; Ann E Kelley
Journal:  Psychopharmacology (Berl)       Date:  2007-02-23       Impact factor: 4.530

Review 4.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

5.  Amygdala-prefrontal cortical circuitry regulates effort-based decision making.

Authors:  Stan B Floresco; Sarvin Ghods-Sharifi
Journal:  Cereb Cortex       Date:  2006-02-22       Impact factor: 5.357

6.  Differential involvement of serotonin and dopamine systems in cost-benefit decisions about delay or effort.

Authors:  F Denk; M E Walton; K A Jennings; T Sharp; M F S Rushworth; D M Bannerman
Journal:  Psychopharmacology (Berl)       Date:  2004-12-10       Impact factor: 4.530

7.  Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy.

Authors:  Lucile Capuron; Giuseppe Pagnoni; Marina F Demetrashvili; David H Lawson; Fiona B Fornwalt; Bobbi Woolwine; Gregory S Berns; Charles B Nemeroff; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2007-02-28       Impact factor: 7.853

8.  Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats.

Authors:  W Hauber; P Neuscheler; J Nagel; C E Müller
Journal:  Eur J Neurosci       Date:  2001-10       Impact factor: 3.386

9.  Pharmacological characterization of performance on a concurrent lever pressing/feeding choice procedure: effects of dopamine antagonist, cholinomimetic, sedative and stimulant drugs.

Authors:  M S Cousins; W Wei; J D Salamone
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

10.  Nucleus accumbens dopamine depletions alter relative response allocation in a T-maze cost/benefit task.

Authors:  M S Cousins; A Atherton; L Turner; J D Salamone
Journal:  Behav Brain Res       Date:  1996-01       Impact factor: 3.332

View more
  41 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

2.  Assessment of a glycine uptake inhibitor in animal models of effort-related choice behavior: implications for motivational dysfunctions.

Authors:  Samantha E Yohn; Daniela Alberati; Merce Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2017-01-12       Impact factor: 4.530

Review 3.  The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond.

Authors:  John D Salamone; Merce Correa; Eric J Nunes; Patrick A Randall; Marta Pardo
Journal:  J Exp Anal Behav       Date:  2012-01       Impact factor: 2.468

Review 4.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

5.  Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.

Authors:  John D Salamone; Andrew M Farrar; Laura Font; Vatsal Patel; Devra E Schlar; Eric J Nunes; Lyndsey E Collins; Thomas N Sager
Journal:  Behav Brain Res       Date:  2009-03-03       Impact factor: 3.332

Review 6.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

7.  Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists.

Authors:  Marta Pardo; Laura López-Cruz; Noemí San Miguel; John D Salamone; Mercè Correa
Journal:  Psychopharmacology (Berl)       Date:  2015-02-03       Impact factor: 4.530

Review 8.  Dopamine/adenosine interactions involved in effort-related aspects of food motivation.

Authors:  John D Salamone; Merce Correa
Journal:  Appetite       Date:  2009-07-25       Impact factor: 3.868

Review 9.  Adenosine hypothesis of schizophrenia--opportunities for pharmacotherapy.

Authors:  Detlev Boison; Philipp Singer; Hai-Ying Shen; Joram Feldon; Benjamin K Yee
Journal:  Neuropharmacology       Date:  2011-02-17       Impact factor: 5.250

10.  Dopamine, behavioral economics, and effort.

Authors:  John D Salamone; Merce Correa; Andrew M Farrar; Eric J Nunes; Marta Pardo
Journal:  Front Behav Neurosci       Date:  2009-09-07       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.